Synapse - Jonathan Rosenberg

Search Within

Jonathan Eric Rosenberg

Results (520)

Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade

Journal Article

Hamidi, H.; Senbabaoglu, Y.; Beig, N.; Roels, J.; Manuel, C.; Guan, X.; Koeppen, H.; Assaf, Z. J.; Nabet, B. Y.; Waddell, A.; more...
Cancer Cell (2024)

Fulltext@MSK | Save

DNA damage response alterations predict for neoadjuvant chemotherapy sensitivity in muscle-invasive bladder cancer: A correlative analysis of the SWOG S1314 trial

Journal Article

Iyer, G.; Tangen, C. M.; Sarfaty, M.; Regazzi, A. M.; Lee, I. L.; Fong, M.; Choi, W.; Dinney, C. P. N.; Flaig, T. W.; Thompson, I. M. Jr; more...
JCO Precision Oncology (2024)

Fulltext@MSK | Save

Rogaratinib plus atezolizumab in cisplatin-ineligible patients with FGFR RNA-overexpressing urothelial cancer: The FORT-2 phase 1b nonrandomized clinical trial

Journal Article

Sweis, R. F.; Gajate, P.; Morales-Barrera, R.; Lee, J. L.; Necchi, A.; De Braud, F.; Penel, N.; Grünwald, V.; Maruzzo, M.; Meran, J.; more...
JAMA Oncology (2024)

Fulltext@MSK | Save

Gene and protein expression of MAGE and associated immune landscape elements in non-small-cell lung carcinoma and urothelial carcinomas

Journal Article

Faiena, I.; Adhikary, S.; Schweitzer, C.; Astrow, S. H.; Grogan, T.; Funt, S. A.; Bot, A.; Dorff, T.; Rosenberg, J. E.; Elashoff, D. A.; more...
Journal of Immunotherapy (2024)

Fulltext@MSK | Save

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001)

Meeting Abstract

Gupta, S.; Ballman, K. V.; Apolo, A. B.; Sridhar, S. S.; Chen, R. C.; Wen, Y.; Yen, A. E.; Grivas, P.; Tan, A. L.; Baghaie, S.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation

Meeting Abstract

Apolo, A. B.; Ballman, K. V.; Sonpavde, G. P.; Berg, S. A.; Kim, W. Y.; Parikh, R. A.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer

Meeting Abstract

Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes

Meeting Abstract

Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results

Meeting Abstract

Sternschuss, M.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Goh, A. C.; Cha, E. K.; Donat, S. M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Defining molecular features associated with microsatellite instability and response to immune checkpoint blockade in urothelial carcinoma

Meeting Abstract

Alam, S. M.; Teo, M. Y.; Woo, J.; Sarfaty, M.; Funt, S. A.; Aggen, D. H.; Lee, C. H.; Carlo, M. I.; Gandhi, J.; Ratna, N.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save